Answers are grounded in this paper and cite their sources.
The increasing prevalence of health-care-associated as well as community-associated infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and the failure of MRSA infections to respond to standard therapy with vancomycin may soon change the epidemiology of pathogens causing skin and soft tissue infections and pneumonia, ultimately changing the way antimicrobial regimens are selected for the treatment of these common infections.1 In addition, the continuous spread of multidrug-resistant Streptococcus pneumoniae (MDRSP) and failure of S. pneumoniae infections to respond to commonly used antibiotics, such as advanced macrolides, respiratory fluoroquinolones, and cephalosporins, will limit clinicians’ ability to effectively manage pneumonia and other invasive pneumococcal infections.2 Ceftaroline, a newly approved broad-spectrum cephalosporin reviewed in this issue of AJHP,3 is active against S. aureus, including strains that are resistant to methicillin and vancomycin; S. pneumoniae (including MDRSP); respiratory pathogens (e.g., Haemophilus influenzae, Moraxella catarrhalis); and other gram-negative bacteria. In clinical trials, ceftaroline was found to be noninferior to vancomycin with or without aztreonam in the treatment of patients with complicated skin and skin structure infections (cSSSIs) and noninferior to ceftriaxone with or without clarithromycin in the treatment of hospitalized patients with community-acquired pneumonia (CAP). These characteristics, along with a favorable safety profile, make ceftaroline an attractive addition to the arsenal of β-lactams, a well-established class of antibiotics. Ceftaroline could soon replace combination therapy for the treatment of cSSSIs if it proves to be cost-effective. Ceftaroline could also have an important role in the empirical treatment of moderate- to-severe CAP. However, ceftaroline is not stable against several β-lactamases, rendering it inactive against bacteria that can produce AmpC β-lactamases and extended-spectrum β-lactamases, which cause a large percentage of cSSSIs.4–7 Forest Laboratories, the manufacturer of ceftaroline, is developing a new β-lactamase inhibitor, NXL-104, in an effort to boost the activity of ceftaroline against β-lactamase-producing bacteria.8 In addition, there is no evidence that ceftaroline is active against atypical pathogens such as Mycoplasma pneumoniae and Chlamydophila pneumoniae, which cause a large percentage of community-acquired bacterial pneumonias.
No takes yet. Share an insight, caveat, or question.
Elias B. Chahine (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: